Content Type: Article

  • IPEM 2022 | Key Takeaways

    IPEM 2022 | Key Takeaways

    ARTICLE

    IPEM 2022 | Key Takeaways

    September 2022

    Read time: 2 min

    Key takeaways
    Overview

    After an insightful conference in Cannes, our partners have compiled some of the key takeaways from IPEM 2022.

    As well as exploring the private equity landscape in the UK, Germany, France and Italy, we also explore the outlook for investment funds and forecast opportunities ahead for M&A.

    To read our full takeaways please click here.

    In depth
    Authors

    Aymen Mahmoud

    Partner

    London – 22 Bishopsgate

    More insights

  • What are the retirement plan dollar limits for 2023?

    What are the retirement plan dollar limits for 2023?

    ARTICLE / CLIENT ALERT

    What are the retirement plan dollar limits for 2023?

    October 25, 2022

    Read time: 2 min

    Key takeaways
    Overview

    The Secretary of the Treasury announced the 2023 limits for qualified retirement plans and IRAs based on cost of living increases. The Consumer Price Index for all Urban Consumers is the benchmark used to determine the index. With a cost-of-living increase of 8.3 percent (the largest cost-of-living increase since 1982), most of the dollar limits are increasing for 2023 as noted in the table on page two.

    IRS Notice 2022-55 sets forth the annual dollar limitations on benefits and contributions to qualified plans, effective Jan. 1, 2023, as required under Section 415(d) of the Internal Revenue Code. For 2023, the cap on employee deferrals increases to $22,500, catch-up contributions increase from $6,500 to $7,500 and the annual additions limit for 401(k), 403(b) and other defined contribution plans increases to $63,000.

    For 2023, highly compensated employees, who participate in both qualified and non-qualified plans, will have a greater amount of their compensation allocated to their qualified plan due to the increase in the compensation limit from $305,000 to $330,000.

    Employers and Plan Sponsors of qualified retirement plans should communicate the new limits for 2023 to their plan participants. We are available to advise you on updating your enrollment materials, summary plan descriptions, employee handbooks and other employee communications. If you have any questions about the new limits or any other employee benefit matters, please feel free to contact one of the authors.

    .

    Authored by Mark E. Brossman, David Cohen, Ian L. Levin, Ronald E. Richman and Susan E. Bernstein.

    In depth
    Authors

    Mark E. Brossman

    Partner

    New York – 919 Third Avenue

    David M. Cohen

    Partner

    New York – 919 Third Avenue

    Ian L. Levin

    Partner

    New York – 919 Third Avenue

    Ronald E. Richman

    Partner

    New York – 919 Third Avenue

    More insights

  • UK Medical Device Regulator Proposes a 12 Month Delay for UKCA Requirements and the New Medical Device Regulations

    UK Medical Device Regulator Proposes a 12 Month Delay for UKCA Requirements and the New Medical Device Regulations

    ARTICLE / CLIENT ALERT

    UK Medical Device Regulator Proposes a 12 Month Delay for UKCA Requirements and the New Medical Device Regulations

    October 24, 2022

    Read time: 4 min

    Key takeaways
    Overview

    The law referred to in this article has changed. Please contact the authors for further information and an updated position.

    On Friday 21st October 2022, the Medicines and Healthcare Products Regulatory Agency (MHRA) wrote to the medical device industry to explain its intention:

    • To extend the current standstill period by twelve months from July 2023 to July 2024. This means that valid CE marks would continue to be accepted in Great Britain (GB) and the requirement to obtain a UK Conformity Assessed (UKCA) mark has been delayed until July 2024; and
    • To introduce the new medical device regulations in July 2024.

    This news will come as welcome relief to manufacturers in the sector following widely published reports of a backlog in processing UKCA applications at approved bodies across the UK.

    In depth

    Importantly, the extension is not yet confirmed by law so we expect further updates to the MHRA website and new legislation to be issued.

    This extension was widely expected following delays in introducing the new medical device regulatory framework.

    The specific details of the new UK medical device framework have yet to be published following the UK government consultation on the proposed changes which began in 2021. The government response to the consultation published in June 2022 indicated that the new GB medical device regulations will be closely aligned the EU Medical Device Regulations 2017.

    The MHRA timetable for implementation initially contemplated that the consultation response for the new framework would be published in March 2022 with the regulations laid before parliament by the end of June 2022. Under World Trade Organisation (WTO) rules, the MHRA is also required to notify the WTO and the WTO must publish the draft regulations for a period of at least 60 days for comment before the regulations are laid.

    The MHRA has said that it continues to work on the development of the future regulations. The likely timeline appears to be:

    • New medical device regulations notification to WTO: early 2023
    • New medical device regulations laid before parliament: Spring 2023
    • New post-market surveillance requirements: Spring 2023
    • New medical device regulations come into force: July 2024
    • Timeline for new transitional periods commence: July 2024.

    The government response in June 2022 indicated that there would be fairly generous transitional periods in the new medical device framework. The response said that the arrangements would allow, at a minimum, products to be placed on the market as follows:

    • General medical devices: until either the certificate expires or for three years after the new regulations take effect (whichever occurred sooner); and
    • In Vitro Diagnostics: until either the certificate expires or five years after the new regulations take effect (whichever is sooner).

    These transitional provisions would not apply if there were significant changes in design or intended purpose. In addition, all products which benefit from transitional arrangements are likely to need to comply with the post-market requirements.

    In its letter on 21 October 2022, the MHRA also acknowledged the shortage of UK approved bodies and noted that it was proactively working with six organisations that have applied to become UK approved bodies. Currently, there are only four designated UK approved bodies.

    This news also comes in the week that the MHRA also released guidance on Software and AI as Medical Device Change Programme Roadmap setting out proposals to implement new legislation and further guidance intending to clarify what medical device requirements mean in the context of software and AI and more closely align with global rules such as the IMDRF.

    Authors

    Sharon Lamb

    Partner

    London – 22 Bishopsgate

    Bella North

    Senior Associate

    London – 22 Bishopsgate

    More insights

  • HPE NEW YORK 2022: WHAT INVESTORS NEED TO KNOW NOW ABOUT SOURCING CAPITAL IN TODAY’S MARKET

    HPE NEW YORK 2022: WHAT INVESTORS NEED TO KNOW NOW ABOUT SOURCING CAPITAL IN TODAY’S MARKET

    ARTICLE

    HPE NEW YORK 2022: WHAT INVESTORS NEED TO KNOW NOW ABOUT SOURCING CAPITAL IN TODAY’S MARKET

    October 21, 2022

    Read time: 4 min

    Key takeaways
    Overview

    During this session, McDermott Partners Samantha Koplik and Stephanie McCann moderated a panel that provided critical insights for investors to consider when sourcing capital to finance healthcare deals in today’s challenging leveraged loan market.

    Session panelists included:

    • Peter Dahms, Managing Director, Capital Markets, Oxford Finance
    • Sam Goldworm, Managing Director East Coast Originations and Head of Capital Markets, WhiteHorse Capital
    • Alex Greeley, Partner, Linden Capital Partners
    • Bryan Rupprecht, Managing Director and Head of Healthcare, MidCap Financial
    In depth

    Top takeaways included:

    1. Inflation, interest rate hikes and valuation dislocation are some of the biggest challenges facing the leveraged loan market today. As a result of these pressures, there is less capital available and lenders have decreased their hold sizes. One panelist said that loans are increasingly being clubbed together, resulting in higher pricing because “the last dollar in is going to set the price.”
    2. The challenges of 2022 will create strong headwinds in 2023. It was noted that “private markets don’t settle the way public markets do” so it will take some time for seller expectations to lower and for valuations to settle in the private market. As a result, lenders predict there will be less acquisition financing for the next few months, and they will also be more selective about which deals they choose to finance.
    3. Despite the challenges of today’s leveraged loan market, a lot of market terms have remained unchanged. Earnings before interest, taxes, depreciation and amortization addbacks typically remain uncapped, and borrowers are still negotiating for post-closing operational flexibility. However, lenders expect to see credit agreement terms tighten around the margins. One panelist shared that the healthcare space has historically had a lot of flexibility for de novo run rate adjustments and that “over the past six to nine months these have gotten very lax.” They expect to see more pushback on these types of adjustments going forward.
    4. For years, sponsors have modeled their deals on their ability to easily leverage debt, particularly in the add-on context. As multiples increase, incremental financing will become less attractive, and sponsors and borrowers will need to look to junior capital to fill the gap. The panelists noted that bringing in non-cash pay junior capital can be extremely beneficial for sponsors and borrowers, especially when utilizing an incremental would trigger most-favored nations provisions and increase pricing.
    5. Loan market challenges will create a few bumps for healthcare investing, but the industry is expected to remain steady and resilient. “Big picture, healthcare will do well moving forward,” one panelist said. There will, however, be differences between the healthcare sectors, particularly those with large labor components. It was noted that “there’s no cataclysmic event within healthcare,” but investors will need to be smart about selecting sectors and financing structures.
    Authors

    Samantha R. Koplik

    Partner

    New York – One Vanderbilt Avenue

    Stephanie S. McCann

    Partner

    Chicago

    More insights

  • HPE NEW YORK 2022: STRATEGIES FOR VALUE INVESTING IN 2022 AND BEYOND

    HPE NEW YORK 2022: STRATEGIES FOR VALUE INVESTING IN 2022 AND BEYOND

    ARTICLE

    HPE NEW YORK 2022: STRATEGIES FOR VALUE INVESTING IN 2022 AND BEYOND

    October 21, 2022

    Read time: 3 min

    Key takeaways
    Overview

    During this session, Felicia Gerber Perlman, McDermott partner and global head of the Firm’s Business Restructuring Practice Group, and Olivia Mauro Guthorn, managing director at Apollo Global Management, explored the challenges facing the healthcare industry today and shared strategies for value investing in light of those challenges.

    In depth

    Top takeaways included:

    1. During a discussion about the impact of wage inflation, it was noted that labor costs are the single biggest focus for current healthcare investments. In response to how to decide when increased labor costs present an opportunity for value investing, the panelists explained that core labor inflation is sticky but wage inflation based on staffing shortages and demand for contract labor could improve with increases in supply or decreases in demand. Additionally, a potential recession could be good for wage inflation that was driven by staffing shortages by increasing the number of workers looking for employment. It was also suggested that healthcare sectors reliant on labor could see an improvement in labor costs relative to the market in a recession.
    2. When talking about shifts in the care model following the pandemic, the panelists noted that COVID-19 accelerated certain trends evident in pre-pandemic healthcare (e.g., shifting care out of emergency rooms and into urgent care clinics), but it’s too early to tell which changes will be permanent. Non-COVID-19 utilization across subspecialties has been weak without clear indications as to the cause. This creates an interesting value investing opportunity for underutilized subspecialties and the potential for high returns when demand for services returns, however, it is difficult to predict when demand will increase and which subspecialties will see those impacts first.
    3. At one point, the panelists touched on the No Surprises Act and whether it would result in value investing opportunities for any particular sectors. Their conclusion? The act is currently more of a headwind than an opportunity for investment. Industry participants have been surprised with how difficult the arbitration process has been, which has impacted the ability of care providers to get cash in the door for services rendered. This has also caused challenges for certain care providers with high concentrations of private payors because there is no clear investment thesis on creating value by investing in providers with exposure to this issue
    Authors
    More insights

  • IRS Announces 2023 Employee Benefit Plan Limits

    IRS Announces 2023 Employee Benefit Plan Limits

    ARTICLE / CLIENT ALERT

    IRS Announces 2023 Employee Benefit Plan Limits

    October 21, 2022

    Read time: 3 min

    Key takeaways
    Overview

    The Internal Revenue Service (IRS) recently announced the cost-of-living adjustments to the applicable dollar limits for various employer-sponsored retirement and welfare plans for 2023. All dollar limits that are subject to adjustment for cost-of-living increases will increase for 2023. Separate adjustment amounts were released by the Social Security Administration.

    In depth

    The IRS and the Social Security Administration announced the cost-of-living adjustments to the applicable dollar limits on various employer-sponsored retirement and welfare plans and the Social Security wage base for 2023. The table below compares the applicable dollar limits for certain employee benefit programs and the Social Security wage base for 2022 and 2023.*

    RETIREMENT PLAN LIMITS (guidance link) 2022 Δ 2023
    Annual compensation limit $305,000 ↑ $330,000
    401(k), 403(b) & 457(b) before-tax contributions $20,500 ↑ $22,500
    Catch-up contributions (if age 50 or older) $6,500 ↑ $7,500
    Highly compensated employee threshold $135,000 ↑ $150,000
    Key employee officer compensation threshold $200,000 ↑ $215,000
    Defined benefit plan annual benefit and accrual limit $245,000 ↑ $265,000
    Defined contribution plan annual contribution limit $61,000 ↑ $66,000
    Employee stock ownership plan (ESOP) limit for determining the lengthening of the general five-year distribution period $245,000 ↑ $265,000
    ESOP limit for determining the maximum account balance subject to the general five-year distribution period $1,230,000 ↑ $1,330,000
    HEALTH AND WELFARE PLAN LIMITS (guidance links here and here) 2022 Δ 2023
    Health Flexible Spending Accounts
    Maximum salary reduction limit $2,850 ↑ $3,050
    Health FSA Carryover Limit $570 ↑ $610
    Dependent Care Flexible Spending Accounts±
    If employee is married and filing a joint return or if the employee is a single parent $5,000 = $5,000
    In employee is married but filing separately $2,500 = $2,500
    Excepted Benefit Health Reimbursement Arrangements (EBHRAs) $1,800 ↑ $1,950±
    Qualified Transportation Fringe Benefit and Qualified Parking (monthly limit) $280 ↑ $300
    High Deductible Health Plans (HDHP) and Health Savings Accounts (HSA)
    HDHP – Maximum annual out-of-pocket limit (excluding premiums):
    Self-only coverage $7,050 ↑ $7,500
    Family coverage $14,100 ↑ $15,000
    HDHP – Minimum annual deductible:
    Self-only coverage $1,400 ↑ $1,500
    Family coverage $2,800 ↑ $3,000
    HSA – Annual contribution limit:
    Self-only coverage $3,650 ↑ $3,850
    Family coverage $7,300 ↑ $7,750
    Catch-up contributions (age 55 or older)± $1,000 ═ $1,000
    SOCIAL SECURITY WAGE BASE (guidance link) 2022 Δ 2023
    Social Security Maximum Taxable Earnings $147,000 ↑ $160,200

    Plan sponsors should update payroll and plan administration systems for the 2023 cost-of-living adjustments and should incorporate the new limits in relevant participant communications, like open enrollment materials and summary plan descriptions.

    For further information about applying the new employee benefit plan limits for 2023, contact your regular McDermott lawyer.


    * The dollar limits are generally applied on a calendar year basis; however, certain dollar limits are applied on a plan-year, tax-year, or limitation-year basis.

    ± Not indexed for cost-of-living adjustments, with the exception of limited guidance issued for certain years.

     

    Authors

    Jeffrey M. Holdvogt

    Partner

    Chicago

    Jacob M. Mattinson

    Partner

    Chicago

    More insights

  • HPE New York 2022: Getting Your Deals to the Finish Line in an Evolving Environment

    HPE New York 2022: Getting Your Deals to the Finish Line in an Evolving Environment

    ARTICLE

    HPE New York 2022: Getting Your Deals to the Finish Line in an Evolving Environment

    October 21, 2022

    Read time: 3 min

    Key takeaways
    Overview

    In this session, Krist Werling, Partner & Co-Head of Private Equity, and David Ivill, Partner & Healthcare Private Equity Practice Area Leader, moderated a panel that provided insight on how investment bankers are getting deals done, and the concerns of the Buyer and Seller’s they represent in the process.

    Session panelists included:

    • Ryan Bell, Managing Director, Moelis & Company
    • Michael Dodds, Managing Director, Jefferies & Company
    • Mark Francis, Managing Director, Head of Healthcare, Houlihan Lokey
    • Fred Levenson, Partner & Co-Head of Private Equity, McDermott Will & Emery
    In depth

    Top takeaways included:

    1. Deals are trending to take longer to get over the finish line. Buyers are approaching the changes in the market with a wide variety of views and differing confidence levels. The fluctuating interest rates impact cash flow and impact a Buyer’s approach to a deal. Sellers should expect an increased scrutiny on the deal process, including QOE analysis and legal due diligence process. The Buyer’s diligence process is likely to be stricter than years past, the Buyer will want to do more initial diligence to gain a full understanding of the investment opportunity. Buyers are less likely to glance over EBITDA decreases that were common from 2020 to early 2022.
    2. While interest rates may make getting the deal done harder, it does not mean deals are stopping. However, both Buyers and Sellers should have a conviction to the process, invest and showcase the high quality attributes and have confidence in their respective teams to get the deal across the finish line.
    3. Similar to the Seven Steps of Grieving, Bankers must take the responsibility to get both Buyers and Sellers through the various steps of the deal and show them the light at the end of the tunnel. With financing taking longer, with the process being more detail oriented, with less interested parties in the market, Sellers will need to find the right Buyer to get a deal done.
    4. European funds are hyper focused on the healthcare market, however, it is Buyer beware, as there is a slight uptick in distressed situations.
    Authors

    Kristian A. Werling

    Partner

    Chicago

    David S. Ivill

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • HPE New York 2022 | Critical Antitrust Issues Impacting Healthcare Services: Enforcement Outlook + How to Plan for Transactions

    HPE New York 2022 | Critical Antitrust Issues Impacting Healthcare Services: Enforcement Outlook + How to Plan for Transactions

    ARTICLE

    HPE New York 2022 | Critical Antitrust Issues Impacting Healthcare Services: Enforcement Outlook + How to Plan for Transactions

    October 21, 2022

    Read time: 3 min

    Key takeaways
    Overview

    During this session, Partners Ashley Fischer and Krist Werling discussed the current environment of antitrust review of healthcare private equity transactions, including the JAB Consumer Products consent order issued by the Federal Trade Commission (FTC) this summer, and what parties should keep in mind when planning for transactions to avoid deal pitfalls.

    Session panelists included:

    • Ashley Fischer, Partner, McDermott Will & Emery
    • Krist Werling, Partner, McDermott Will & Emery
    In depth

    Top takeaways included:

    1. There is heightened antitrust scrutiny with an increased focus on private equity transactions and transactions in the healthcare industry. FTC Chair Lina Khan and the Head of the US Department of Justice’s Antitrust Division Jonathan Kanter, as well as their lieutenants, have recently made several comments reflecting their opinions that healthcare private equity should focus on short-term profits and saddle businesses with debt and that the private equity model is fundamentally at odds with the competition. The antitrust statutes are designed to protect a free and open marketplace, and the agencies believe that if there is sufficient market competition, there will be lower prices and better quality and access for consumers and patients.
    2. This summer, the FTC issued a consent order against JAB designed to prevent the private equity firm from further consolidating veterinary clinics. The FTC concluded that there were market concentration issues with JAB’s proposed transactions as they involved veterinary clinics in several geographies where there were only a few competitors to begin with. As a remedy to such antitrust concerns, the FTC required that JAB divest clinics in several geographies. Notably, the consent order also imposed prior notice and prior approval provisions obligating JAB to provide the agency with prior notice of additional veterinary acquisitions moving forward regardless of the size of such in certain areas and obtain its affirmative consent to acquisitions in other areas regardless of the size of such proposed transactions.
    3. Early termination of review periods for Hart-Scott-Rodino Act filings is still unavailable to parties, and there have been increased instances of protracted agency review periods. Whether a transaction will require divestiture or result in a prior notice and prior consent requirement on a party will depend on the nature of the company/platform, its past conduct and history of acquisitions, and the competitive landscape in the specific geographies at play. Accordingly, transactions involving buyers that have little to no market overlap with the target business or in geographies where there are no market concentration issues are less likely to be of concern to antitrust agencies. Parties with market overlap should begin planning an antitrust analysis as soon as possible.
    Authors

    Ashley M. Fischer

    Partner

    Chicago

    Kristian A. Werling

    Partner

    Chicago

    More insights

  • U.S. Department of Labor Proposes New Worker Classification Rule

    U.S. Department of Labor Proposes New Worker Classification Rule

    ARTICLE / CLIENT ALERT

    U.S. Department of Labor Proposes New Worker Classification Rule

    October 21, 2022

    Read time: 5 min

    Key takeaways
    Overview

    On Oct. 11, 2022, the U.S. Department of Labor (“DOL”) issued a proposed rule that, if implemented, would update the test under the Fair Labor Standards Act (“FLSA”) for determining whether a worker is considered an employee or an independent contractor. The FLSA establishes employees’ (but not independent contractors’) rights to minimum wage and overtime pay.

    The proposed rule attempts to return the test to the standard existing prior to its modification during the Trump Administration to focus on the degree of control workers have over their job duties and their opportunities for profit or loss. The proposed rule is likely to result in more workers being classified as employees rather than independent contractors.

    In the Notice of Proposed Rulemaking, which is now open for public comment, the DOL concluded that the Trump-era approach did not adequately comport with the FLSA’s text and purpose, and was a departure from years of case law that applied the economic reality test.

    Proposed Rule

    The rule would establish a totality-of-the-circumstances economic realities test in which the ultimate inquiry is “whether the worker is economically dependent on the employer for work” (employee status) or “in business for themself” (independent contractor status).

    The six factors under the proposed economic realities test are:

    1. Whether the worker’s managerial skill affect the worker’s opportunity for profit or loss;
    2. The degree of investments by the worker relative to the employer’s investments;
    3. The degree of permanence of the work relationship, which typically also involves considerations of exclusivity and whether the individual also works for other entities;
    4. The nature and degree of the employer’s control over the worker;
    5. The extent to which the work performed is an integral part of the employer’s business; and
    6. Whether the worker uses specialized skills to perform the work and whether those skills contribute to business-like initiative.

    Additional factors beyond the six listed above may be relevant if they indicate that an individual is in business for themselves rather than economically dependent on the employer. The proposal represents a return to the longstanding totality-of-the-circumstances approach in which the factors do not have a predetermined weight and are considered “in view of the economic reality of the whole activity.”

    The public has until Nov. 28, 2022 to submit comments on the proposed rule. After the comment period closes, the DOL has the opportunity to incorporate feedback into the final rule.

    Other Tests

    The IRS uses a multi-factor test for determining employee or independent contractor classification. The IRS characterizes the relevant factors into behavioral control, financial control and relationship of the parties.

    In addition to federal regulation, employers must also comply with state and local standards for proper classification of workers as employees or independent contractors. Some states have established stricter standards than the federal test for determining whether a worker is an employee or independent contractor. New Jersey, for example, among other states, has adopted the “ABC” test which presumes a worker is an employee unless three requirements are met:

    1. The individual has been and will continue to be free from control or direction over the performance of work performed, both under contract of service and in fact; and
    2. The work is either outside the usual course of the business for which such service is performed, or the work is performed outside of all the places of business of the enterprise for which such service is performed; and
    3. The individual is customarily engaged in an independently established trade, occupation, profession or business.

    New York City adopted the Freelance Isn’t Free Act in 2017, which aims to enhance protections for independent contractors by establishing the right to a written contract, timely and full payment, and protection from retaliation. The law applies to “freelance workers” who are defined as people who are “hired or retained as [] independent contractor[s] by a hiring party to provide services in exchange for compensation.”

    Authored by Mark E. Brossman, Ronald E. Richman, Martin L. Schmelkin, Max Garfield, Scott A. Gold and Donna K. Lazarus.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2022 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Mark E. Brossman

    Partner

    New York – 919 Third Avenue

    Ronald E. Richman

    Partner

    New York – 919 Third Avenue

    Martin L. Schmelkin

    Partner

    New York – 919 Third Avenue

    Max Garfield

    Partner

    New York – 919 Third Avenue

    Donna K. Lazarus

    Partner

    New York – 919 Third Avenue

    More insights

  • Bankruptcy Court Slams U.S. Trustee’s Attempted Disqualification of Investment Banker

    Bankruptcy Court Slams U.S. Trustee’s Attempted Disqualification of Investment Banker

    ARTICLE / CLIENT ALERT

    Bankruptcy Court Slams U.S. Trustee’s Attempted Disqualification of Investment Banker

    October 21, 2022

    Read time: 10 min

    Key takeaways
    Overview

    The “connections” of the chairman (“W”) of the debtor’s investment bank (“S”) to his family’s foundations do “not give rise to an actual, active conflict of any kind,” held a bankruptcy judge in the Southern District of New York on Oct. 17, 2022. In re SAS A.B., 2022 WL 10189110, *3 (Bankr. S.D.N.Y. Oct. 17, 2022). According to the court, it “is only through strained speculation [by the U.S. Trustee] that a potential issue can even be posited.” Accord, In re Harold & Williams Dev. Co., 977 F.2d 906 (4th Cir. 1992) (rejected UST and bankruptcy court’s per se prohibition of professional’s serving as attorney and accountant; “horrible imaginings alone cannot be allowed to carry the day;” remanded for fact-specific inquiry whether foreseeable tasks presented inherent conflict or potential breach of confidence), quoting In re Martin, 817 F.2d 175, 183 (1st Cir. 1987) (same; “Not every conceivable conflict must result in” disqualification).

    Courts routinely rely upon “ethical walls”, said the court, when “large investment banking firms have affiliates or divisions that engage in debt trading, stock trading, or other activities that arguably might give rise to potential issues if a person engaged in those activities were permitted to communicate with the investment bankers.” Because the U.S. Trustee (“UST”) had “endorsed the use of ethical walls… in a countless number of [other cases],” the court saw “no reason why such arrangements would not be sufficient to protect against any risks that one might posit with respect to [W’s] association with” his family foundations. Id., at *3. The court then approved S’s wall in the case.

    Relevance

    Every professional seeking retention in a bankruptcy case must file a “verified statement… setting forth the person’s connections with the debtor, creditors, any other party in interest, their respective attorneys and accountants, the United States Trustee, or any person employed in the office of the United States Trustee.” Fed. R. Bankr. P. 2014(a). The professional’s retention under Bankruptcy Code (“Code”) § 327(a) thus requires disclosure of any information bearing on the court’s consideration of § 327(a)’s two-prong test (disinterestedness and no adverse interest). The professional’s disclosure must be “spontaneous, timely and complete.” Rome v. Braunstein, 19 F.3d 54, 59 (1st Cir. 1994). Failure to disclose relevant information is itself ground for reduction of fees or removal from the case. In re Textile Indus., Inc., 198 B.R. 902, 905 (Bankr. M.D.N.C. 1996) (accountant holding previously undisclosed pre-bankruptcy claim against debtor immediately removed from case); In re Filene’s Basement, Inc., 239 B.R. 850, 858 (Bankr. D. Mass. 1999) (law firm having a definite adverse interest removed from case because it “failed fully to disclose its connections with parties in interest [i.e. litigation targets] as required by Rule 2014”).

    Facts

    The debtors sought to retain “S” as a co-investment banker. The UST argued that S was “not ‘disinterested’ and therefore not eligible to be employed as the Debtors’ investment banker [under] the terms of [Code] §§ 101(14) and 327….”

    S “is a commercial and investment bank with operations in Scandinavia” and “has acted as both a commercial bank and as an investment banker to the Debtors in connection with many transactions….” The debtor’s business plan “will require new capital raises and debt-to-equity conversions.” Because the relevant Scandinavian governmental entities “are stakeholders in the Debtors, and many of the Debtors’ other creditors and parties of interest are located in Scandinavia,” the debtors claimed to have needed “an investment banker with experience and contacts in Scandinavia,” making S “well-suited” (perhaps uniquely suited) to provide the necessary services.” 2022 WL 10189110, at *1.

    No party had challenged S’s qualifications, but only the UST claimed that S was not “disinterested” as required by Code §§ 327 and 101(14). Section § 327 “permits the employment of professional advisors who are ‘disinterested persons’; Section § 101(14) provides that term to exclude those who, among other things, were “a creditor, …equity security holder, or an insider,” or who “have in interest materially adverse to the interest of the estate or of any class of creditors or equity security holders, by reason of any direct or indirect relationship to, or connection with, or interest in, the debtor, or for any other reason.” (emphasis added). According to the UST, S had “a number of ‘connections’… that raised ‘disinterestedness’ issues that should disqualify [it] from acting as an interest banker in these cases.”

    Disinterestedness

    The Chairman’s Family Foundations. The family of the chair of S’s board of directors, W, is associated with sixteen private foundations (“Foundations”). The Foundations owned an entity known as “W Investments” that also owns 3.42 percent of the debtor’s common stock, worth “approximately $13.2 million, compared to total assets of the Foundations in excess of $24.3 billion.” The Debtors made full disclosure “in ample time to permit the [UST] or other parties in interest to file objections.” Id., at *2. But the UST argued here that W’s “association with the Foundations could create conflicts of interest for [S].” For example, reasoned the UST, the Foundations’ interests “might cause” S “to favor equity interests of the kind that” the Foundations indirectly own “or might prompt W to issue instructions that the investment bankers do so.” The court rejected UST’s hypothetical and theoretical fears, explaining that “the question to be decided… is whether a given set of facts gives rise to a bias against the estate or to an economic interest that actually has a significant potential to affect the professional’s loyalty, to undercut the value of the professional’s services, or to give rise to a dispute in which the estate would be a rival party.” Id., citing In re Arochem Corp., 176 F.3d 610, 623 (2d Cir. 1999).

    The court “simply [could not] see how [W’s] connection to the Foundations gives rise to a ‘materially adverse interest’ under these standards,” stressing the following indisputable facts:

    • Neither W nor S itself owned any stock in the Debtor;
    • W is associated with the Foundations, but had no personal interest in the investments of the assets of the Foundations and S itself had no such interests;
    • The Foundations’ indirect “small equity stake” in the debtors “is just a tiny fraction of the overall asset of the Foundations and is not material to the Foundations”;
    • W has “no day-to-day involvement with the [S] investment banker teams” working on the proposed engagement;
    • S is not the sole investment banker, but is a co-investment banker with another admittedly disinterested entity and W has no “interest [in] or control over” that entity;
    • S will “bar communications between [W] and the investment bankers;” and
    • W “will not participate in any discussions or votes at directors’ meetings of the Foundations that in any way pertain to the Debtors.”

    Id.

    The court rejected the UST’s position that the “ethical walls” here were insufficient as a matter of law, as noted earlier. In any event, the court required that the S investment banking team “have no communications with [W], the . . . Foundations, [and] other groups [within S] and individuals associated with any of those entities or groups about [S’s] work for the Debtors and about any non-public information that the investment banking team has about the Debtors.” These protections, said the court, make it “quite clear that [W’s] association with the… Foundations, and the… Foundations’ indirect ownership of a small portion of [the debtor’s] outstanding equity, do not raise a disqualifying ‘materially adverse interest’ as to [S’s] retention as co-investment banker.” Id., at *4.

    Other Makeweight Assertions Rejected. The court also rejected the UST’s other similar arguments as “far too attenuated” to be disqualifying. Because of the “ethical wall” applied above, the court rejected a challenge to S’s pre-bankruptcy sale of an interest in outstanding Debtor loans because the UST made no showing that “the Debtors made recoverable transfers in connection with” the sale of S’s interests. As to the UST’s assertion that S “might be a logical entity to approach for exit financing,” the court again stressed that “the speculative loss of a potential future borrowing opportunity… ought [not] to be considered as a presently disabling factor in [S’s] retention.” Id., at *5.

    The Debtor’s Bank Accounts With S. The court further rejected the UST’s argument that S “might be required to give advice as to whether the Debtor’s bank deposits should be moved,” creating possible conflicts. Id. According to the court, this “contention… just reflects a misunderstanding of the services that investment banks provide,” which have “nothing to do with… where funds are deposited.” It was hardly “a basis on which to refuse” S’s retention.” When the UST argued that “the sheer number of [S’s] prior connections” created possible future risks, the court stressed the requirement of “specific issues” for disqualification, not “speculation” about “some unknown issue [that] might arise.” Id.

    S’s Purported Creditor Status

    Code § 101(14) excludes a “creditor” from “disinterested” status. Because S had been paid for its pre-bankruptcy services, the UST initially claimed S was a creditor but only dropped this line of attack during a court hearing because it had no “facts” showing that pre-bankruptcy payments “were improper in any way, or [were recoverable] as preferences.” Id., at *6. Similarly, the debtors’ pre-bankruptcy payments made to an S affiliate for credit card services were not preferential and did not make S a creditor. Id., at *7. Finally, as to S’s guarantees of certain debtor obligations, S “waived any and all prepetition claims it has or may have for indemnification, reimbursement, or other similar amounts with respect to the guarantees,” thereby eliminating the “creditor” issue.

    Comments

    1. The UST’s broad attack on the Debtors’ proposed retention of an investment bank shows how the UST has been scrutinizing financial advisor retentions in the past few years. Some of the scrutiny is valid, but why the issues raised here had not been resolved prior to judicial intervention is puzzling. S apparently had not been represented by counsel. Counsel for the debtors and the creditors’ committee could not represent S, but the debtors’ counsel effectively showed why the debtors properly wanted to retain S.
    2. The court here also showed its understanding of investment banker services. That has not always been true. A little more than thirty years ago, however, a New York bankruptcy judge unfairly described the work of investment bankers in an reorganization cases as follows: “Whenever we have dealt with investment bankers and financial advisors we have been left with the strong impression that for them the debtor is the cash cow to be milked, Chapter 11 the milking parlor and the Judge the milking stool…. It is clear the investment bankers want to sip the cream and leave the skimmed milk for others.” In re Drexel Burnham Lambert Grp., Inc., 133 B.R. 13, 26 (Bankr. S.D.N.Y. 1991). See also In re Hillsborough Holdings Corp., 125 B.R. 837 (Bankr. M.D. Fla. 1991) (questioning value of investment bankers’ services). The SAS opinion now shows how investment bankers can and do add value in reorganization cases.

    Authored by Michael L. Cook.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or the author.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2022 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors
    More insights